- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05626712
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes (CREATE-1)
July 12, 2023 updated by: Creative Medical Technology Holdings Inc
Clinical Trial to Evaluate the Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes (CREATE-1)
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The proposed study is a Phase I/IIa randomized, controlled clinical trial to evaluate CELZ-201 therapy as an intervention for the treatment of recent onset Type 1 Diabetes.
The objective is to determine the safety and efficacy of CELZ-201 administration, based on the timing and dose of CELZ-201 treatment.
Subjects who meet eligibility criteria will be randomized to treatment or control groups, in a 2:1 ratio.
Subjects in the Group I (Treatment Group, n=12) will receive standard of care for type 1 diabetes and CELZ-201 within 1 month from enrollment (within 180 days of diagnosis).
Subjects in Group II (Control Arm, n=6) and will receive enhanced standard of care for type 1 diabetes.
Study Type
Interventional
Enrollment (Estimated)
18
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Creative Medical Technology
- Phone Number: (702) 588-1890
- Email: clinicaltrials@creativemedicaltechnology.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Diabetes Research Institute, University of Miami Miller School of Medicine
-
Principal Investigator:
- Camillo Ricordi, MD
-
Sub-Investigator:
- Rodolfo Alejandro, MD
-
Contact:
- Camillo Ricordi, MD
- Phone Number: 305-243-5321
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject must be able to understand and provide signed informed consent.
- Males and females, 18-35 years of age.
- Diagnosis of T1D within 180 days, with stimulated C-peptide peak level >0.6 ng/mL as assessed by 4-hour MMTT at the time of Visit 0 (screening).
- Diagnosed with T1D, according to ADA standard criteria, and confirmed by positivity to at least two islet autoantibodies, GAD65, IA-2, or ZnT8.
- Mentally stable and able to comply with the procedures of the study protocol
- Subjects must be willing to comply with "standard-of-care" diabetes management.
- Subjects with eGFR >80 ml/min/1.73m2
- Female subjects of childbearing potential must have a negative pregnancy test upon study entry.
- Female (and male) subjects with reproductive potential must agree to use two FDA approved methods of birth control for the entire duration of the study. Potential subjects of childbearing potential should agree to use effective contraception for the entire 2-year period.
- Adequate venous access to support study required blood draws.
Exclusion Criteria:
- Inability or unwillingness of a subject to give written informed consent or comply with study protocol.
- BMI>28 kg/m.
- HbA1c > 9%
- Subjects with poorly controlled hypertension as defined by systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.
- Subjects with any history of cardiac disease, including but not limited to myocardial infarction, uncompensated heart failure, fluid overload, as well as any clinically significant abnormality identified on prior cardiac stress test, angiogram evaluation, or echocardiogram.
- Subjects with liver disease, portal hypertension, any coagulopathy (including history of Factor V deficiency) or long-term anti-coagulant therapy (except low-dose aspirin). Other hepatic conditions including hepatic anatomic abnormalities or variants that would place the individual at increased risk in the judgment of the investigator are also considered exclusionary.
- Symptomatic cholecystolithiasis; acute or chronic pancreatitis; or current symptomatic peptic ulcer disease.
- Subjects with uncontrolled thyroid disease: thyroid stimulating hormone <0.3 mU/L or >5 mU/L; free T4 <5.0 ug/dL or >11.0 ug/dL.
- Any of the following laboratory findings: hemoglobin <11.5 g/dL (females) or <13.2 g/dL (males); leukocytes <3,000/μL; neutrophils <1,500/μL; lymphocytes <800/μL; platelets <100,000/μL; elevation in AST and ALT >2 x ULN (upper limit of normal); LDL cholesterol >160; Triglycerides >3 x ULN; total bilirubin >1.5 x ULN.
- Screening laboratory evidence consistent with significant chronic active infection (i.e.., hepatitis B and C, tuberculosis, and HIV), and IGRA Tuberculosis (Tb) test during screening
- Ongoing acute infections, e.g., acute respiratory tract, urinary tract, or gastrointestinal tract infections.
- Subjects with eating disorders.
- Ongoing or anticipated use of diabetes medications other than insulin.
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening.
- Recent recipient of any licensed or investigational live attenuated vaccine(s) within 6 weeks of randomization.
- Patients who have participated in previous clinical studies, other than observational studies, will be excluded.
- Concomitant therapy with immunosuppressive drugs, immunomodulators, or cytotoxic agents, or previous therapy less than 3 months from randomization.
- History or diagnosis of malignancy with the exception of a history of localized basal or squamous cell carcinoma.
- Any history of gastroparesis or other severe gastrointestinal disease.
- Presence of an allograft.
- Diagnosed or self-reported drug or alcohol abuse.
- An individual who has a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.
- Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both females and males of childbearing age to use a reliable and effective form of contraception, for the entire 2-year duration of the study.
- Inability to perform any of the assessments required for endpoint analysis.
- Known history of serious allergic reactions, including anaphylaxis to CELZ-201 or its preparation components. Specifically, patients with a prior history of heparin induced thrombocytopenia or any other adverse reaction to heparin, will be excluded.
- The investigator believes that participating in the trial is not in the best interest of the patient, or the investigator considers patient unsuitable for enrollment (such as unpredictable risks or subject compliance issues).
- Positive for coronavirus disease (COVID)-19 by PCR or evidence of active infection per local institutional standards.
- Allergy to iodine contrast or anesthesia
- For female subjects: Pregnant, nursing, or planning to become pregnant during the course of entire duration of the study (approximately little over two years) or unwillingness to comply with contraceptive requirements.
- For male subjects: Male subjects with a female partner who is planning to become pregnant with the male subject during the entire course of the study or unwillingness to comply with contraceptive requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CELZ-201 Treatment Group
Participants in this group will receive a single dose of CELZ-201, in addition to standard of care of care for Type 1 Diabetes treatment.
|
Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment.
Perinatal tissue derived cells will be administered at a dose of 1x10^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
|
Placebo Comparator: Control Group
Participants in this group will receive standard of care for Type 1 Diabetes only.
|
Enhanced standard of care for Type 1 Diabetes treatment only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events
Time Frame: 6 months
|
The primary outcome to be assessed is tolerability and safety of the CELZ-201 therapy.
The incidence of adverse events (grade 2 or above as per CTCAE version 5.0) in both groups at 6 months.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events
Time Frame: 12 months
|
Incidence of adverse events (grade 2 or above as per CTCAE version 5.0) in both groups at 12 months.
|
12 months
|
Number of Participants with Adverse Events
Time Frame: 24 months
|
Incidence of adverse events (grade 2 or above as per CTCAE version 5.0) in both groups at 24 months.
|
24 months
|
Glycosylated HbA1C
Time Frame: 12 months
|
Changes in glycosylated HbA1c (%)
|
12 months
|
Insulin Requirement
Time Frame: 12 months
|
Changes in exogenous insulin requirement
|
12 months
|
Islet Autoantibody Levels
Time Frame: 12 months
|
Changes in islet autoantibody levels GAD65 (U/mL), IA2 (U/mL), and ZnT8 (U/mL)
|
12 months
|
Alloreactive Antibody Levels
Time Frame: 12 months
|
Changes in alloreactive antibody levels (U/mL)
|
12 months
|
C-peptide during a 4-hour MMTT
Time Frame: 12 months
|
Changes in fasting, peak stimulated and AUC C-peptide (ng/mL) during a 4-hour MMTT
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Camillo Ricordi, MD, University of Miami, Diabetes Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 7, 2023
Primary Completion (Estimated)
January 31, 2025
Study Completion (Estimated)
January 31, 2026
Study Registration Dates
First Submitted
November 7, 2022
First Submitted That Met QC Criteria
November 15, 2022
First Posted (Actual)
November 25, 2022
Study Record Updates
Last Update Posted (Actual)
July 14, 2023
Last Update Submitted That Met QC Criteria
July 12, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CELZ-201-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on CELZ-201 Administration
-
Creative Medical Technology Holdings IncNot yet recruitingChronic Low-back Pain | Degenerative Disc DiseaseUnited States
-
Hookipa Biotech GmbHRecruitingHPV-Related Squamous Cell CarcinomaUnited States, Spain, Netherlands
-
TWi Biotechnology, Inc.CompletedType 2 Diabetes MellitusUnited States, Taiwan
-
Modulation Therapeutics, Inc.H. Lee Moffitt Cancer Center and Research InstituteRecruitingUveal Melanoma | MetastaticUnited States
-
Royal Prince Alfred Hospital, Sydney, AustraliaCompleted
-
QurAlis CorporationRecruitingAmyotrophic Lateral SclerosisCanada, Germany, Netherlands, Ireland, United Kingdom, Belgium
-
Suzhou Connect Biopharmaceuticals, Ltd.Active, not recruiting
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompleted
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedPsoriasisGermany, Israel, Poland, Spain
-
PegBio Co., Ltd.CompletedType2 Diabetes MellitusChina